A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

计划入组 318 人 · 首次发布于 2023 年 2 月 23 日

Effectiveness of Pharmacotherapy Follow-up Care in Outpatients With Type 2 Diabetes Mellitus

计划入组 60 人 · 首次发布于 2017 年 6 月 22 日

Placebo Controlled Study of Sublingual Salvinorin A

计划入组 8 人 · 首次发布于 2010 年 6 月 24 日

SGLT inhibitors(Jiangsu Hansoh Pharmaceutical Co. Ltd.)

NMUR2 agonists (Takeda Pharmaceutical)

PL-1 (Protelight Pharmaceutical)

Hansoh Pharmaceutical Group Company Limited

China

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

China

Hansoh Pharma

China

Hansoh Pharma's HS-20093 Granted Breakthrough Therapy Designation for Lung Cancer

Hansoh Pharma's Aumolertinib Plus Chemotherapy Shows Positive Phase III Results in EGFR-Mutated NSCLC

Hansoh Pharma's HS-20093 ADC Granted Breakthrough Therapy Designation for ES-SCLC